Cannabinoids for the Treatment of Pain: The Case of Sickle-Cell Anemia
January 22, 2026
At the January CMCR Investigators’ Meeting, Daniele Piomelli, Ph.D., Distinguished Professor at UC Irvine and Editor-in-Chief of Cannabis and Cannabinoid Research, presented findings on the potential of cannabinoids for treating pain associated with Sickle Cell Disease (SCD). While acknowledging a recent large-scale clinical trial for chronic low back pain, Dr. Piomelli focused on the urgent need to identify specific clinical pain conditions amenable to cannabinoid interventions using robust preclinical models.
Using a humanized mouse model of SCD, Dr. Piomelli’s team demonstrated that acute administration of low-dose THC (1 mg/kg) effectively normalized disease-specific hyperalgesia and allodynia. Interestingly, during subacute (14-day) administration, efficacy was maintained for mechanical allodynia without tolerance, whereas tolerance developed rapidly for cold hyperalgesia, suggesting modality-specific responses. The presentation also highlighted the efficacy of cannabidiol (CBD). Unlike the high doses typically used in epilepsy, lower doses of CBD (10 and 30 mg/kg) provided robust analgesic effects in the SCD model with no observed tolerance.
When THC and CBD were co-administered at low doses (0.45 mg/kg THC and 5.08 mg/kg CBD), Dr. Piomelli observed a synergistic effect. He detailed the potential mechanisms driving this interaction: pharmacokinetically, the combination appeared to slow metabolism, increasing circulating levels of both cannabinoids. Pharmacodynamically, the combination significantly elevated levels of the endocannabinoid 2-arachidonoylglycerol (2-AG), a phenomenon also recently observed in human subjects. At the molecular level in the spinal cord, the compounds showed complementary anti-inflammatory actions, with CBD reducing pro-inflammatory IL-1β and THC increasing anti-inflammatory IL-10.
Concluding his talk, Dr. Piomelli argued that these solid preclinical data justify the development of a properly designed, sufficiently powered clinical trial for SCD. He advocated for oral administration to ensure consistent dosing and metabolic activation, suggesting that a targeted, condition-specific approach is necessary to move beyond the failures of previous broad-spectrum clinical methodologies.
Daniele Piomelli, PhD, MD (hon) is the Louise Turner Arnold Chair in Neurosciences and Distinguished Professor of Anatomy & Neurobiology, Pharmacology & Biological Chemistry at UC Irvine. Dr. Piomelli is a world-renowned cannabis scientist who directs the NIDA Center of Excellence ICAL (Impact of Cannabinoids Across the Lifespan) and UCI's Center for the Study of Cannabis. Dr. Piomelli is Editor-in-Chief of Cannabis and Cannabinoid Research, a premier peer-reviewed journal entirely dedicated to the study of cannabis, its derivatives, and their endogenous counterparts in the human body. He is author of >470 peer-reviewed articles, three full-length books, and >38 patents.